Your consent is required to display this content from vimeo - Privacy Settings
Date of first investment: 2023
About Endomag
Endomag is at the forefront of revolutionising breast cancer care. Based in Cambridge, UK, the business develops and sells breast surgery localization and lymphatic tracing technologies. The Claret European Growth Capital Fund III first invested in Endomag in 2023, fuelling the company’s mission to deliver innovative solutions for the detection and treatment of breast cancer.
Trusted by physicians and patients globally:
- 500,000 total patients treated
- 1,350+ Hospitals
- 45+ countries
“Claret’s funding is supporting Endomag in further growing the business, bringing their breast cancer treatment products to even more patients.” – Dr. Eric Mayes, CEO, Endomag